Vaginal Estradiol and Cognitive Function: What the Evidence Actually Shows

Does vaginal estradiol improve cognition?

Vaginal estradiol is prescribed for vaginal symptoms. The estradiol vaginal cream 0.01% label covers moderate to severe symptoms of vulvar and vaginal atrophy due to menopause [2].

The cognitive question has instead been studied with systemic estrogen. Two randomized trials measured thinking and memory in postmenopausal women taking oral or transdermal estrogen, and neither found a benefit on the cognitive tests they used [1][3].

What the estradiol trials actually measured

ELITE assigned healthy postmenopausal women to oral 17-beta estradiol 1 mg a day or placebo; women with a uterus also received cyclic micronized progesterone vaginal gel or placebo [1]. After a mean of 57 months, 567 women were included in the analyses. On verbal memory the estradiol-minus-placebo standardized difference was -0.06 (95% CI -0.22 to 0.09), which was not significant (p=0.33), and executive function and global cognition showed no significant differences either. The investigators concluded that estradiol started within 6 years of menopause does not affect these abilities differently than therapy begun 10 or more years after menopause [1].

The KEEPS Cognitive and Affective Study enrolled 693 of the 727 women taking part in KEEPS and followed them for up to 4 years. They were randomized to oral conjugated equine estrogens 0.45 mg a day (220 women), transdermal estradiol 50 mcg a day (211 women), or placebo (262 women), with micronized progesterone 200 mg a day for the first 12 days of each month in the two active-treatment groups [3]. Cognition did not improve with either active treatment. Oral conjugated equine estrogens did improve depression and anxiety scores, while transdermal estradiol performed like placebo on mood, and the authors noted the results cannot be extended beyond 4 years [3].

In both trials the estrogen was systemic, not a vaginal product: oral estradiol in ELITE, oral conjugated equine estrogens or transdermal estradiol in KEEPS-Cog [1][3].

The WHI dementia findings and the vaginal question

The Women's Health Initiative did not test estradiol. It tested oral conjugated equine estrogens 0.625 mg a day, alone in 10,739 women with a prior hysterectomy and combined with medroxyprogesterone acetate 2.5 mg a day in 16,608 women with a uterus [8][9].

Its memory substudy, WHIMS, reported an increased risk of probable dementia in women 65 and older: over 4 years with conjugated estrogens plus medroxyprogesterone [4], and over 5.2 years with conjugated estrogens alone [5].

The labels limit how far that finding travels. The Climara patch label says only daily oral conjugated estrogens 0.625 mg were studied in the estrogen-alone substudy, so the relevance of the WHI findings to lower CE doses, other routes of administration or other estrogen-alone products is not known, and those risks cannot be definitively excluded [5]. The estradiol vaginal cream label goes further: in the absence of comparable data, it says the risks should be assumed to be similar for other doses of conjugated estrogens and other dosage forms of estrogens [2]. In its November 2025 labeling request, FDA noted that the WHI dementia studies enrolled women aged 65 to 79 [6].

What the vaginal estradiol cream label says

The estradiol vaginal cream 0.01% prescribing information in effect on 2026-04-13 carries a boxed warning titled for endometrial cancer, cardiovascular disorders, breast cancer and probable dementia. It states that estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia [2].

Its warnings section states that systemic absorption may occur with the cream and that the warnings, precautions and adverse reactions associated with oral estrogen treatment should be taken into account [2]. Its adverse reaction list includes dementia among central nervous system reactions reported with estrogen therapy, without a frequency [2].

These statements come from the cream label. Inserts and rings are separate products with separate labels; the estradiol ring Estring was among the first six menopausal hormone therapy labels FDA approved updated wording for on 2026-02-12 [7][10].

What changed at FDA in 2025 and 2026

On 2025-11-10 FDA asked manufacturers of menopausal hormone therapy to remove boxed-warning language on cardiovascular disease, breast cancer and probable dementia, keep the endometrial cancer boxed warning on systemic estrogen-alone products, drop the lowest-effective-dose-for-the-shortest-time recommendation, and add consideration of starting therapy for moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause [6].

On 2026-02-12 FDA approved updated labels for six products, including one topical vaginal estrogen, Estring [7][10]. FDA's published list of updated labels names Prometrium, Divigel, Cenestin, Enjuvia, Estring and Bijuva [10]. The estradiol vaginal cream 0.01% label version in effect on 2026-04-13 still carries the longer boxed warning that names probable dementia [2].

Do any guidelines recommend estrogen for cognition?

The Endocrine Society's 2015 guideline on menopausal symptoms states that current evidence does not justify using menopausal hormone therapy to prevent coronary heart disease, breast cancer or dementia [11]. The 2022 North American Menopause Society position statement recommends low-dose vaginal estrogen, vaginal dehydroepiandrosterone or oral ospemifene for bothersome genitourinary symptoms in women who do not have an indication for systemic hormone therapy [12]. The same statement rates the benefit-risk ratio as less favorable for women who start hormone therapy more than 10 years after menopause or after age 60, and attributes that to greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia [12].